RevvityRVTYEarnings & Financial Report
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
RVTY Q4 FY2025 Key Financial Metrics
Revenue
$772.1M
Gross Profit
N/A
Operating Profit
$111.7M
Net Profit
$98.4M
Gross Margin
N/A
Operating Margin
14.5%
Net Margin
12.7%
YoY Growth
5.9%
EPS
$0.86
Revvity Q4 FY2025 Financial Summary
Revvity reported revenue of $772.1M (up 5.9% YoY) for Q4 FY2025, with a net profit of $98.4M (up 3.9% YoY) (12.7% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $772.1M |
|---|---|
| Net Profit | $98.4M |
| Gross Margin | N/A |
| Operating Margin | 14.5% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Revvity Q4 FY2025 revenue of $772.1M breaks down across 5 segments, led by Immunodiagnostics at $240.8M (31.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Immunodiagnostics | $240.8M | 31.2% |
| Life Sciences | $191.4M | 24.8% |
| Reproductive Health | $149.3M | 19.3% |
| Segment Operating Income | $132.0M | 17.1% |
| Software | $62.3M | 8.1% |
Revvity Revenue by Segment — Quarterly Trend
Revvity revenue by segment across the last 4 reported quarters, showing how each business line (such as Immunodiagnostics and Life Sciences) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Immunodiagnostics | $240.8M | $212.7M | $218.8M | $197.6M |
| Life Sciences | $191.4M | $178.1M | — | — |
| Reproductive Health | $149.3M | — | $135.6M | $126.8M |
| Segment Operating Income | $132.0M | $130.0M | $135.0M | $119.3M |
| Software | $62.3M | $52.3M | — | — |
Revvity Annual Revenue by Year
Revvity annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.9B).
Revvity Quarterly Revenue & Net Profit History
Revvity results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $772.1M | +5.9% | $98.4M | 12.7% |
| Q3 FY2025 | $698.9M | +2.2% | $46.7M | 6.7% |
| Q2 FY2025 | $720.3M | +4.1% | $53.9M | 7.5% |
| Q1 FY2025 | $664.8M | +2.3% | $42.2M | 6.4% |
| Q4 FY2024 | $729.4M | +8.7% | $94.6M | 13.0% |
| Q3 FY2024 | $684.0M | -3.5% | $94.4M | 13.8% |
| Q2 FY2024 | $691.7M | +2.5% | $55.4M | 8.0% |
| Q1 FY2024 | $649.9M | +485.5% | $26.0M | 4.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $649.9M | $691.7M | $684.0M | $729.4M | $664.8M | $720.3M | $698.9M | $772.1M |
| YoY Growth | 485.5% | 2.5% | -3.5% | 8.7% | 2.3% | 4.1% | 2.2% | 5.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $13.43B | $13.42B | $12.77B | $12.39B | $12.36B | $12.36B | $12.14B | $12.17B |
| Liabilities | $5.59B | $5.55B | $4.85B | $4.73B | $4.72B | $4.81B | $4.76B | $4.92B |
| Equity | $7.85B | $7.87B | $7.92B | $7.67B | $7.64B | $7.56B | $7.38B | $7.25B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $147.6M | $158.6M | $147.9M | $174.2M | $128.2M | $134.3M | $138.5M | $182.0M |